GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Medicure Inc (TSXV:MPH) » Definitions » Capex-to-Operating-Income

Medicure (TSXV:MPH) Capex-to-Operating-Income : 2.29 (As of Mar. 2024)


View and export this data going back to 1999. Start your Free Trial

What is Medicure Capex-to-Operating-Income?

Capex-to-Operating-Income measures a company's investments in physical assets such as property, industrial buildings or equipment to its operating income.

Medicure's Capital Expenditure for the three months ended in Mar. 2024 was C$-0.09 Mil. Its Operating Income for the three months ended in Mar. 2024 was C$0.04 Mil.

Hence, Medicure's Capex-to-Operating-Income for the three months ended in Mar. 2024 was 2.29.


Medicure Capex-to-Operating-Income Historical Data

The historical data trend for Medicure's Capex-to-Operating-Income can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Medicure Capex-to-Operating-Income Chart

Medicure Annual Data
Trend May14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Capex-to-Operating-Income
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - 0.26 -

Medicure Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Sep23 Dec23 Mar24
Capex-to-Operating-Income Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.10 0.08 - - 2.29

Competitive Comparison of Medicure's Capex-to-Operating-Income

For the Drug Manufacturers - Specialty & Generic subindustry, Medicure's Capex-to-Operating-Income, along with its competitors' market caps and Capex-to-Operating-Income data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Medicure's Capex-to-Operating-Income Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Medicure's Capex-to-Operating-Income distribution charts can be found below:

* The bar in red indicates where Medicure's Capex-to-Operating-Income falls into.



Medicure Capex-to-Operating-Income Calculation

Medicure's Capex-to-Operating-Income for the fiscal year that ended in Dec. 2023 is calculated as

Capex-to-Operating-Income=- Capital Expenditure / Operating Income
=- (-0.27) / -0.854
=N/A

Medicure's Capex-to-Operating-Income for the quarter that ended in Mar. 2024 is calculated as

Capex-to-Operating-Income=- Capital Expenditure / Operating Income
=- (-0.087) / 0.038
=2.29

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Medicure  (TSXV:MPH) Capex-to-Operating-Income Explanation

Capex-to-Operating-Income assesses how much emphasis a company is placing upon investing in capital-intensive projects. The ratio is generally a good gauge to quantify how much focus on growth a company has. Typically, smaller companies that are still growing and expanding will have a higher Capex to Operating Income Ratio, since such businesses are likely investing more in physical assets. Lower ratios could indicate that a company has reached maturity and it is no longer pursuing aggressive growth.


Medicure Capex-to-Operating-Income Related Terms

Thank you for viewing the detailed overview of Medicure's Capex-to-Operating-Income provided by GuruFocus.com. Please click on the following links to see related term pages.


Medicure (TSXV:MPH) Business Description

Traded in Other Exchanges
Address
2 - 1250 Waverley Street, Winnipeg, MB, CAN, R3T 6C6
Medicure Inc is a biopharmaceutical company. It is involved in the research, clinical development, and commercialization of human therapeutics for the United States hospital market. Further, it also operates a specialty pharmacy in the United States of America. The company's present focus is the sale and marketing of its cardiovascular products, AGGRASTAT, ZYPITAMAG, and developing its e-commerce and mail order pharmaceutical business. The company operates in two segments namely, Marketing and distribution of commercial products and, Retail and mail order pharmacy. The majority of the company's revenue is generated from the marketing and distribution of the commercial products segment.
Executives
Albert David Friesen Director, Senior Officer

Medicure (TSXV:MPH) Headlines

No Headlines